financetom
Business
financetom
/
Business
/
Bandhan Bank Q2 profit down 5% at Rs 920 cr
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bandhan Bank Q2 profit down 5% at Rs 920 cr
Nov 2, 2020 6:16 AM

Bandhan Bank on Monday reported 5.3 percent decline in net profit at Rs 920 crore for September quarter of the current fiscal year. The bank clocked a net profit of Rs 971.80 crore in the same period of 2019-20.

Total income grew 22 percent to Rs 2,304.90 crore in July-September 2020-21 as against Rs 1,889.30 crore in the year-ago period, Bandhan Bank said in a regulatory filing. Net interest income of the Kolkata-headquartered lender jumped 25.8 percent to Rs 1,923.1 crore during the quarter while the non-interest income grew 6.1 percent to Rs 381.8 crore.

Bandhan Bank said it has reported the highest ever quarterly profit before tax at Rs 1,233 crore during the period under review. Net Interest Margin (annualised) in the quarter fell to 8 percent against 8.2 percent in year-ago period. During the quarter, the bank took accelerated additional provision on standard advances amounting to Rs 300 crore. With this provision and the additional standard assets provision that bank is carrying in micro banking portfolio, the total additional provision in books stands at Rs 2,096 crore, it said.

The bank’s gross non-performing assets fell to 1.2 percent (Rs 874 crore) of gross advances as of September 30, 2020 as against 1.8 percent (Rs 1,064.20 crore) by the year-ago same period. Net NPAs too improved to 0.4 percent (Rs 262.50 crore) from 0.6 percent (Rs 336.90 crore).

”As the moratorium ended on 31st August 2020 coupled with robust rural performance, we have seen an all-round improvement in collection, disbursement and deposits. On deposits front, we have witnessed the best ever quarter whereas on the disbursement front, we are close to pre-COVID-19 level.”

Collections have seen a steady improvement month-on-month and is expected to reach near normal in the next 90 days. We now look forward to accelerate the business in H2FY 21,” Managing Director and CEO Chandra Shekhar Ghosh said. Total Advances grew 19.4 percent to Rs 76,614.6 crore as on September 30, 2020. Total deposits increased 34.4 percent to Rs 66,127.7 crore.

Bandhan Bank stock was trading at Rs 305.50 on BSE, up 5.62 percent from the previous close.

First Published:Nov 2, 2020 3:16 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Noble Completes Acquisition of Diamond Offshore Drilling
Noble Completes Acquisition of Diamond Offshore Drilling
Sep 6, 2024
10:57 AM EDT, 09/04/2024 (MT Newswires) -- Noble (NE) said Wednesday it has completed its acquisition of Diamond Offshore Drilling, expanding its position among offshore drilling companies and adding around $2 billion of backlog. The company said it issued more than 24.2 million Class A shares to former Diamond shareholders and its total backlog has grown to $6.7 billion with...
Axsome Therapeutics Says FDA Accepts Potential Migraine Treatment Resubmission
Axsome Therapeutics Says FDA Accepts Potential Migraine Treatment Resubmission
Sep 6, 2024
10:54 AM EDT, 09/04/2024 (MT Newswires) -- Axsome Therapeutics ( AXSM ) said Wednesday the US Food and Drug Administration has accepted the resubmission of its New Drug Application for AXS-07 to potentially treat migraine. The FDA has classified it as a Class 2 resubmission, with a Prescription Drug User Fee Act target action date of Jan. 31, 2025, the...
Amgen aims to treat liver, kidney diseases with obesity drug
Amgen aims to treat liver, kidney diseases with obesity drug
Sep 6, 2024
By Puyaan Singh Sept 4 (Reuters) - Amgen ( AMGN ) will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney diseases in its late-stage trial, the company's CEO Robert Bradway said on Wednesday. Speaking at a Morgan Stanley healthcare conference, Bradway described MariTide as a next-generation obesity drug due to...
Reports of dollar's demise are greatly exaggerated, JPMorgan says
Reports of dollar's demise are greatly exaggerated, JPMorgan says
Sep 6, 2024
LONDON (Reuters) - Suggestions that the dollar's dominance of the global financial system is ending are wide of the mark, JPMorgan said on Wednesday, despite some dramatic signs of change in commodity markets and certain trading blocs. China's rise and the use of economic sanctions on the likes of Russia mean there is a trend of diversification away from the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved